PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain

Sponsor
University of Houston (Other)
Overall Status
Recruiting
CT.gov ID
NCT05036499
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
130
1
2
29.6
4.4

Study Details

Study Description

Brief Summary

There is a pressing public health need to develop novel interventions that aim to reduce alcohol consumption and concurrent alcohol among hazardous drinkers with comorbid chronic pain. The proposed study will draw upon NIH treatment development guidelines (Stage 1) to translate and innovate past work to address a major public health priority. Specifically, we propose to develop (Phase IA) and pilot test (Phase IB) a brief, integrated, single-session, computer-based personalized feedback intervention (PFI) designed to 1) enhance knowledge regarding adverse pain-related anxiety-alcohol interrelations; and (2) increase motivation and intention to reduce hazardous drinking.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Personalized Feedback Intervention
N/A

Detailed Description

Hazardous alcohol use contributes to mental and physical health problems, disability, and may lead to increased risk of premature death. Among individuals with chronic pain the rate of hazardous alcohol use is elevated compared to the general population, yet, hazardous alcohol users with chronic pain remain an underserved group. There is a critical need to test alternative and complimentary approaches to the implementation of effective interventions to reduce hazardous alcohol use among this high-risk segment of the general population; doing so in an integrated fashion (i.e., jointly targeting alcohol and affective mechanisms that may maintain pain-alcohol associations) may provide a more efficient and targeted intervention approach. Targeting pain-related anxiety, a transdiagnostic vulnerability factor that is prospectively associated with both hazardous drinking and chronic pain, may be beneficial. Thus, more work is needed to evaluate the benefit of targeting elevated pain-related anxiety among hazardous drinkers with chronic pain. Our approach will follow a staged model consistent with NIH guidelines for developing and standardizing behavioral interventions. Phase IB activities will include a proof-of-concept and highly rigorous randomized clinical trial designed to compare pain-related anxiety/alcohol PFI (PA-PFI) to assessment only among a sample of 130 hazardous drinkers with chronic pain who have elevated levels of pain-related anxiety. This study represents an important and pivotal step in the larger landscape of translating basic research to more efficacious strategies for reducing hazardous drinking among underserved populations with medical comorbidities. The proposed intervention would be highly disseminable and relevant to millions of hazardous drinkers with chronic pain. Given the collective public health impact of chronic pain and hazardous drinking, the proposed study will yield findings that enhance scientific knowledge, enhance our understanding of mechanisms in reciprocal pain-alcohol relations, and inform the development of novel treatments for hazardous drinkers with chronic pain with elevated pain-related anxiety that are adaptable and easily implemented across a variety of healthcare settings.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Development of a Personalized Feedback Intervention Targeting Pain-Related Anxiety for Hazardous Drinkers With Chronic Pain
Actual Study Start Date :
Sep 27, 2021
Anticipated Primary Completion Date :
Mar 15, 2024
Anticipated Study Completion Date :
Mar 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Personalized Feedback Intervention (PFI)

Personalized Feedback Intervention targeting pain-related anxiety for hazardous drinkers with chronic pain

Behavioral: Personalized Feedback Intervention
Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety

No Intervention: Assessment Only

Assessment only, no active treatment elements

Outcome Measures

Primary Outcome Measures

  1. Hazardous Drinking [2 weeks post intervention]

    Alcohol Use Disorders Identification Test - Scores below 8 (males) and 7 (females) indicate non-hazardous drinking

  2. Hazardous Drinking [1 month post intervention]

    Alcohol Use Disorders Identification Test - Scores below 8 (males) and 7 (females) indicate non-hazardous drinking

  3. Drinking Quantitiy/Frequency [2 weeks post intervention]

    Timeline Follow Back will be used to assess past 2 week drinking quantity and frequency, and an average alcohol consumption variable will be created

  4. Drinking Quantitiy/Frequency [1 month post intervention]

    Timeline Follow Back will be used to assess past 2 week drinking quantity and frequency, and an average alcohol consumption variable will be created

Secondary Outcome Measures

  1. Pain-related Anxiety [Immediately Post intervention]

    A measure of anxiety related to pain (pain anxiety symptoms scale 20) and pain-elicitnig activities. Range of scores from 0-100, with higher scores indicating greater fear and anxiety.

  2. Pain-related Anxiety [2 weeks post intervention]

    A measure of anxiety related to pain (pain anxiety symptoms scale 20) and pain-elicitnig activities. Range of scores from 0-100, with higher scores indicating greater fear and anxiety.

  3. Pain-related Anxiety [1 month post intervention]

    A measure of anxiety related to pain (pain anxiety symptoms scale 20) and pain-elicitnig activities. Range of scores from 0-100, with higher scores indicating greater fear and anxiety.

  4. Motivation to Reduce Drinking [Immediately Post intervention]

    The Alcohol Ladder will be used to assess motivation to reduce drinking on a 0-10 scale, with 0 indicating no motivation to reduce drinking, and 10 indicating 100% intend to reduce drinking.

  5. Motivation to Reduce Drinking [2 weeks post intervention]

    The Alcohol Ladder will be used to assess motivation to reduce drinking on a 0-10 scale, with 0 indicating no motivation to reduce drinking, and 10 indicating 100% intend to reduce drinking.

  6. Motivation to Reduce Drinking [1 month post intervention]

    The Alcohol Ladder will be used to assess motivation to reduce drinking on a 0-10 scale, with 0 indicating no motivation to reduce drinking, and 10 indicating 100% intend to reduce drinking.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥ 21 years of age

  • Current hazardous drinking pattern (AUDIT scores ≥ 8 for males and ≥ 7 for females)

  • Current chronic pain (1) on most days of the week (i.e., 4 or more days per week), (2) at an average weekly severity of 3 or greater on a 0-10 numerical rating scale, and (3) for at least three months in duration

  • Fluent in English

Exclusion Criteria:
  1. Concurrent alcohol or other substance use treatment

  2. Not being fluent in English

  3. Current acute psychiatric distress or thought disorder

  4. Current imminent risk of suicidality

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Houston Houston Texas United States 77204

Sponsors and Collaborators

  • University of Houston
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

  • Study Chair: Michael J Zvolensky, Ph.D., University of Houston

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrew Rogers, Principal Investigator, University of Houston
ClinicalTrials.gov Identifier:
NCT05036499
Other Study ID Numbers:
  • F31AA028694
  • F31AA028694
First Posted:
Sep 5, 2021
Last Update Posted:
Sep 29, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2021